Abstract
Oncology therapies were prominent in the industry news for March, both in immuno-oncology with new subcutaneous formulations being advanced by AstraZeneca and Merck and a novel product driving the merger of Sun Pharma and Checkpoint Therapeutics and in advances in ADCs, both in the clinic (AstraZeneca/Daiichi Sankyo) and in early development deals (Roche/Oxford Biotherapeutics, GV20/Mitsubishi, Whitehawk Therapeutics). In a time when antimicrobial resistance and pandemic risks are of concern, advances in novel antibiotics and antivirals were of note (GSK, Traws). Several items of interesting news of gene therapies and of cell therapies were announced by both big pharma and smaller companies (BMS/2seventybio, AstraZeneca/EsoBiotec, Hologen/MeiraGTx, Neurotec, Orca Bio, Novartis). News of delivery technology advances for small molecules came from Optinose and from Soleno, and a deal technology for the oral delivery of peptides was shared by Opko/Entera.